Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Zh Mikrobiol Epidemiol Immunobiol ; (10): 97-101, 1977 Oct.
Artigo em Russo | MEDLINE | ID: mdl-72469

RESUMO

A method of preparation of subtypical antisera to two determinants of hepatitis B surface antigen (anti-HBs Ag/ay and anti-HBs Ag/ad) is described. The test system obtained was approbated on 1400 antigen-positive sera collected from blood donors and patients suffering from acute and chronic virus hepatitis in various geographical zones of the USSR. HBs Ag/ay proved to prevail (84--100%), HBs Ag/ad was distributed irregularly--from 16% in the European part of the USSR to 0--4% in the republics of the Middle Asia and Siberian regions. HBs Ag/ad was mostly determined in the population of Western regions of the European part of the USSR (the Baltic republics, 43.4%, Moldavia 24.3%).


Assuntos
Antígenos da Hepatite B , Doença Aguda , Doença Crônica , Epitopos , Geografia , Humanos , Sorotipagem , U.R.S.S.
2.
Antibiot Khimioter ; 37(3): 20-2, 1992 Mar.
Artigo em Russo | MEDLINE | ID: mdl-1514862

RESUMO

The efficacy of eremomycin, a new glycopeptide antibiotic, was studied on a model of antibiotic-associated colitis in golden hamsters. The colitis was induced by intraperitoneal or intragastric administration of lincomycin. In a dose of 100 mg/kg administered orally once a day for 5 days eremomycin protected the animals from the lincomycin-induced colitis: some animals survived, the others died in later periods. When the animals were infected with a pathogenetic strain of Clostridium difficile followed by exposure to lincomycin the use of eremomycin produced the similar effect.


Assuntos
Antibacterianos/uso terapêutico , Clostridioides difficile/patogenicidade , Modelos Animais de Doenças , Enterocolite Pseudomembranosa/tratamento farmacológico , Lincomicina/efeitos adversos , Administração Oral , Animais , Clostridioides difficile/efeitos dos fármacos , Cricetinae , Enterocolite Pseudomembranosa/induzido quimicamente , Enterocolite Pseudomembranosa/microbiologia , Glicopeptídeos/uso terapêutico , Injeções Intraperitoneais , Lincomicina/administração & dosagem , Masculino , Mesocricetus , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA